Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter.
Indaptus Therapeutics Stock Performance
NASDAQ INDP opened at $0.82 on Tuesday. Indaptus Therapeutics has a 1 year low of $0.70 and a 1 year high of $3.10. The business’s fifty day moving average is $0.86 and its two-hundred day moving average is $1.10. The stock has a market capitalization of $11.58 million, a P/E ratio of -0.48 and a beta of 1.60.
Wall Street Analyst Weigh In
Separately, Maxim Group cut their target price on Indaptus Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th.
About Indaptus Therapeutics
Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.
Further Reading
- Five stocks we like better than Indaptus Therapeutics
- Which Wall Street Analysts are the Most Accurate?
- How to Protect Your Portfolio When Inflation Is Rising
- The 3 Best Retail Stocks to Shop for in August
- 3 Tech Stocks Defying Sector Weakness and Thriving in 2025
- 3 REITs to Buy and Hold for the Long Term
- Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
